Status:

RECRUITING

A Study on the Impact of Bivalirudin Usage During PCI for High-risk Plaques on Post-PCI Coronary Microcirculation.

Lead Sponsor:

Peking University First Hospital

Conditions:

Coronary Microvascular Dysfunction

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

In this study, investigators enrolled patients with coronary heart disease who were scheduled to undergo percutaneous coronary intervention (PCI) and had high-risk plaques according to computed tomogr...

Detailed Description

Coronary artery disease (CAD) is one of the leading causes of death in China, with nearly 11.39 million patients affected. Percutaneous coronary intervention (PCI) is an important treatment for CAD, b...

Eligibility Criteria

Inclusion

  • aged 18 years or older;
  • diagnosed with non-ST-segment elevation myocardial infarction or unstable angina pectoris;
  • scheduled to undergo elective coronary angiography and intervention;
  • coronary computed tomography angiography showing high-risk plaque features within 3 months prior to the procedure;
  • voluntary participation in the study and signed informed consent.

Exclusion

  • prior PCI of the target vessel within 3 months;
  • cardiogenic shock, active bleeding, bleeding disorders, irreversible coagulation dysfunction, severe liver dysfunction (Child-Pugh class C), severe renal dysfunction (eGFR \< 30 ml/min/1.73m2), and dependence on dialysis;
  • life expectancy less than 1 year;
  • chronic total occlusion of the target vessel;
  • poor opacification of the target vessel, severe vessel overlap or distortion, and inability to completely expose the lesion site;
  • allergy to contrast agents, verapamil, or its excipients;
  • severe uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg);
  • subacute bacterial endocarditis.

Key Trial Info

Start Date :

July 1 2023

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

January 4 2026

Estimated Enrollment :

70 Patients enrolled

Trial Details

Trial ID

NCT05984537

Start Date

July 1 2023

End Date

January 4 2026

Last Update

August 12 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Peking university first hospital

Beijing, Beijing Municipality, China, 10034